Risk factors for autoimmune diseases development after thrombotic thrombocytopenic purpura

Medicine (United States)

Volumn 94, Issue 42, 2015, Pages e1598-

  Roriz, Melanie ^a,b,c   Landais, Mickael ^d   Desprez, Jonathan ^e   Barbet, Christelle ^f   Azoulay, Elie ^f   Galicier, Lionel ^g   Wynckel, Alain ^d   Baudel, Jean Luc ^h   Provot, Francois ⁱ   Pene, Frederic ^j   Mira, Jean Paul ^e   Presne, Claire ^k   Poullin, Pascale ^l   Delmas, Yahsou ^m   Kanouni, Tarik ⁿ   Seguin, Amelie ^o   Mousson, Christiane ^p   Servais, Aude ^q   Bordessoule, Dominique ^r   Perez, Pierre ^s   Chauveau, Dominique ^t   Veyradier, Agnes ^u   Halimi, Jean Michel ^v   Hamidou, Mohamed ^h,w   Coppo, Paul ^d   more..

^a CHU BRETONNEAU   (France)

^b HÔTEL DIEU   (France)

^c CENTRE HOSPITALIER DE VALENCIENNES   (France)

^d SORBONNE UNIVERSITÉ   (France)

^e UNIVERSITÉ PARIS DESCARTES   (France)

^f SAINT LOUIS HOSPITAL   (France)

^g HÔPITAL MAISON BLANCHE   (France)

^h HÔPITAL SAINT ANTOINE   (France)

ⁱ LILLE UNIVERSITY HOSPITAL   (France)

^j ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^k AMIENS UNIVERSITY HOSPITAL   (France)

^l Hôpital de Marseille Conception   (France)

^m HÔPITAL PELLEGRIN   (France)

ⁿ MONTPELLIER UNIVERSITY HOSPITAL   (France)

^o CAEN UNIVERSITY HOSPITAL   (France)

^p Service De Néphrologie   (France)

^q HÔPITAL NECKER ENFANTS MALADES   (France)

^r DUPUYTREN UNIVERSITY HOSPITAL   (France)

^s CHU NANCY BRABOIS   (France)

^t CHU RANGUEIL   (France)

^u HÔPITAL LARIBOISIÈRE   (France)

^v UNIVERSITÉ PARIS SACLAY   (France)

^w INSTITUT GUSTAVE ROUSSY   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CYCLOPHOSPHAMIDE; DOUBLE STRANDED DNA; RITUXIMAB; RO ANTIBODY; STEROID; VINCRISTINE;

ADOLESCENT; ADULT; AGED; ANKYLOSING SPONDYLITIS; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNE HEMOLYTIC ANEMIA; AUTOIMMUNE THYROIDITIS; CROSS-SECTIONAL STUDY; CRYOGLOBULINEMIA; DISEASE REGISTRY; FEMALE; FOLLOW UP; HUMAN; INFLAMMATORY BOWEL DISEASE; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; MIXED CONNECTIVE TISSUE DISEASE; MULTIPLE SCLEROSIS; PREVALENCE; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; PSORIASIS; RAYNAUD PHENOMENON; RELAPSE; RISK FACTOR; SARCOIDOSIS; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIC PURPURA; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT DURATION; VERY ELDERLY; AUTOIMMUNE DISEASES; COMPLICATION; MIDDLE AGED; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AUTOIMMUNE DISEASES; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; PURPURA, THROMBOTIC THROMBOCYTOPENIC; RISK FACTORS; YOUNG ADULT;

EID: 84948135752     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000001598     Document Type: Article

References (44)

1. Crawley JTB, Scully MA. Thrombotic thrombocytopenic purpura: basic pathophysiology and therapeutic strategies. Hematology Am Soc Educ Program. 2013;2013:292-299.
2. George JN, Charania RS. Evaluation of patients with microangiopathic hemolytic anemia and thrombocytopenia. Semin Thromb Hemost. 2013;39:153-160.
3. George JN, Nester CM. Syndromes of microangiopathy. N Eng J Med. 2014;371:654-666.
4. Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med. 1998;339:1585-1594.
5. Bianchi V, Robles R, Alberio L, et al. Von Willebrand factor cleaving protease (ADAMTS13) in thrombotic thrombocytopenic disorders: A severely deficient activity is specific for thrombotic thrombocytopenic purpura. Blood. 2002;100:710-713.
6. Scully M, Hunt BJ, Benjamin S, et al. Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. Br J Haematol. 2012;158: 323-335.
7. Schaller M, Studt JD, Voorberg J, et al. Acquired thrombotic thrombocytopenic purpura. Hämostaseologie. 2013;33:121-130.
8. Feys BH, Roodt J, Vandeputte N, et al. Thrombotic thrombocytopenic purpura directly linked with ADAMTS13 inhibition in the baboon. Blood. 2010;166:2005-2010.
9. Amoura Z, Costedoat-Chalumeau N, Veyradier A, et al. Thrombotic thrombocytopenic purpura with severe ADAMTS13 deficiency in two patients with primary antiphospholipd syndrome. Arthritis Rheum. 2004;50:3260-3264.
10. Trent K, Neustater BR, Lottenberg R. Chronic relapsing thrombotic thrombocytopenic purpura and antiphospholipid antibodies: A report of two cases. Am J Hematol. 1997;54:155-159.
11. Espinosa G, Bucciarelli S, Cervera R, et al. Thrombotic microangiopathic haemolytic anaemia and antiphospholipid antibodies. Ann Rheum Dis. 2004;63:730-736.
12. Nagai K, Kotani T, Takeuchi T, et al. Successful treatment of thrombotic thrombocytopenic purpura with repeated plasma exchange in a patient with microscopic polyangitis. Mod Rheumatol. 2008;18:643-646.
13. Watanabe H, Kitagawa W, Suzuki K, et al. Thrombotic thrombocytopenic purpura in a patient with rapidly progressive glomerulonephritis with both antiglomerular basement membrane antibodies and myeloperoxidase antineutrophils cytoplasmic antibodies. Clin Exp Nephro. 2010;14:598-601.
14. Asamiya Y, Moriyama T, Takano M, et al. Successful treatment with rituximab in a patient with TTP secondary to severe ANCAassociated vasculitis. Intern Med. 2010;49:1587-1591.
15. Yamashita H, Takahashi Y, Kaneko H, et al. Thrombotic thrombocytopenic purpura with an autoantibody to ADAMTS13 complicating Sjögren's syndrome: Two cases and a literature review. Mod Rheumatol. 2012;23:365-373.
16. Toumeh A, Josh N, Narwal R, et al. Refractory thrombotic thrombocytopenic purpura associated with primary Sjögren syndrome treated with rituximab: A case report. Am J Ther. 2012;21:56-60.
17. Suzuki E, Kanno T, Acano T, et al. Two cases of mixed connective tissue disease complicated with thrombotic thrombocytopenic purpura. Fukushima J Med Sci. 2013;59:49-55.
18. Robert V, Eszto P, Perrotz J-L, et al. Treatment by plasmapherisis of a thrombotic thrombocytopenic purpura associated to Still's disease: A case report. Ann Fr Anesth Reanim. 2006;25:532-534.
19. Manadan AM, Harris C, Block JA. Thrombotic thrombocytopenic in the setting of systemic sclerosis. Semin Arthritis Rheum. 2005;34:683-688.
20. Pallot-Prades B, Benvenuto V, Riffat G, et al. Thrombotic thrombocytopenic purpura and ankylosing spondylarthritis: A case report. Rev Med Interne. 1993;14:115-116.
21. Jiang H, An X, Li Y, et al. Clinical features and prognosis factors of thrombotic thrombocytopenic purpura associated with systemic lupus erythematosus: A literature review of 105 cases from 1999 to 2011. Clin Rheumatol. 2014;33:419-427.
22. Letchumanan P, Ng H-J, Lee L-H, et al. A comparison of thrombotic thrombocytopenic purpura in an inception cohort of patients with and without systemic lupus erythematosus. Rheumatology (Oxford). 2009;48:399-403.
23. Musio F, Bohen EM, Yuan CM, et al. Review of thrombotic thrombocytopenic purpura in the setting of systemic lupus erythematosus. Semin Arthritis Rheum. 1998;28:1-19.
24. Kwok SK, Ju JH, Cho CS, et al. Thrombotic thrombocytopenic purpura in systemic lupus erythematosus: risk factors and clinical outcome: A single-centre study. Lupus. 2009;18:16-21.
25. John ML, Scharrer I. Autoimmune disorders in patients with idiopathic thrombotic thrombocytopenic purpura. Hämostaseologie. 2012;32 (Supp1):86-89.
26. Vesely SK, George JN, Lämmle B, et al. ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood. 2003;102:60-68.
27. Coppo P, Wolf M, Veyradier A, et al. Pronostic value of inhibitory anti-ADAMTS13 antibodies in adult-Acquired thrombotic thrombocytopenic purpura. Br J Haematol. 2006;132:166-174.
28. Kremer Hovinga JA, Vesely SK, Terrell DR, et al. Survival and relapse in patients with thrombotic thrombocytopenic purpura. Blood. 2012;115:1500-1501.
29. Coppo P, Veyradier A. Current management and therapeutical perspectives in thrombotic thrombocytopenic purpura. Press Med. 2012;41:163-176.
30. Scully M, Hurt BJ, Benjamin S, et al. Guidelines on the diagnosis and management of thrombotic thrombocytopenic microangiopathies. Br J Haematol. 2012;158:323-335.
31. Froissart A, Buffet M, Veyradier A, et al. Efficacity and safety of first line rituximab in severe, acquired thrombotic thombocytopenic purpura with a suboptimal response to plasma exchange. Experience of the French Thrombotic thrombocytopenic Microangiopathies Reference Center. Crit Care Med. 2012;40:104-111.
32. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40:1725.
33. Shiboski SC, Shiboski CH, Criswell LH, et al. American College of Rheumatology Classification Criteria for Sjögren's Syndrome: A data-driven, expert consensus approach in the SICCA cohort. Arthritis Care Res. 2012;64:475-487.
34. Vitali C, Bombardieri S, Jonsson R, et al. Classification criteria for Sjögren's syndrome: A revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis. 2002;61:554-558.
35. Miyaki S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4:295-306.
36. Scheiflinger F, Knöbl P, Trattner B, et al. Non neutralizing IgM and IgG antibodies to von Willbrand factor-cleaving protease (ADAMTS-13) in a patient with thrombotic thrombocytopenic purpura. Blood. 2003;120:3241-3243.
37. Davidson A, Diamond B. Advances in immunology: Autoimmune disease. N Eng J Med. 2001;345:340-350.
38. Deford C, Reese J, Schwartz A, et al. Multiple major morbidities and increased mortality during long-Term follow-up after recovery from thrombotic thrombocytopenic purpura. Blood. 2013;122: 2023-2029.
39. Lansigan F, Isufi I, Tagoe CE. Microangiopathic haemolytic anaemia resembling thrombotic thrombocytopenic purpura in systemic lupus erythematosus: The role of ADAMTS13. Rheumatology (Oxford). 2011;50:824-829.
40. Gunnarsson I, van Vollenhoven RF. Biologicals for the treatment of systemic lupus erythematosus? Ann Med. 2012;44:225-232.
41. Coppo P, Bengoufa D, Veyradier A, et al. Severe ADAMTS13 deficiency in adult idiopathic thrombotic microangiopathies defines a subset of patients characterized by various autoimmune manifestations, lower platelet count, and mild renal involvement. Medicine (Baltimore). 2004;83:233-244.
42. Blomberg S, Ronnblom L, Wallgren AC, et al. Anti-SSA/Ro antibody determination by enzyme-linked immunosorbent as a supplement to standard immunofluorescence in antinuclear antibody screening. Scand J Immunol. 2000;51:612-617.
43. Arbuckle MR, McClain MT, Rubertone MV, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med. 2003;349:1526-1533.
44. Hie M, Gay J, Galicier L, et al. Preemptive rituximab infusions after remission efficiently prevent relapses in acquired thrombotic thrombocytopenic purpura. Blood. 2014;124:204-210.